Baseline CRP subgroup, mg/L		Participants, n*	Geometric mean baseline CRP, mg/L†	Estimated change in CRP, %	ETD [95% CI], %	Interaction p value
STEP 1						
<1	Semaglutide 2·4 mg	158	0·61 (n=223)	–54	–45 [–59, –28]	0·811
	Placebo	65		–15		
1–3	Semaglutide 2·4 mg	371	1·87 (n=574)	–55	–47 [–55, –37]	
	Placebo	203		–16		
>3	Semaglutide 2·4 mg	773	7·94 (n=1155)	–51	–43 [–50, –35]	
	Placebo	382		–14		
STEP 2						
<1	Semaglutide 2·4 mg	55	0·55 (n=168)	–44	–22 [–45, 10]	vs 1·0 mg: 0·858
	Semaglutide 1·0 mg	54		–28		
	Placebo	59		–3	–43 [–59, –20]	vs placebo: 0·739
1–3	Semaglutide 2·4 mg	111	1·80 (n=361)	–47	–11 [–29, 13]	
	Semaglutide 1·0 mg	133		–41		
	Placebo	117		–14	–38 [–52, –21]	
>3	Semaglutide 2·4 mg	236	7·50 (n=674)	–50	–9 [–24, 9]	
	Semaglutide 1·0 mg	212		–45		
	Placebo	226		–21	–36 [–47, –24]	
STEP 3						
<1	Semaglutide 2·4 mg	34	0·60 (n=50)	–46	–45 [–66, –9]	0·503
	Placebo	16		–2		
1–3	Semaglutide 2·4 mg	97	1·84 (n=148)	–56	–41 [–56, –20]	
	Placebo	51		–26		
>3	Semaglutide 2·4 mg	270	7·92 (n=405)	–63	–51 [–60, –41]	
	Placebo	135		–23		



Change in CRP: Semaglutide 2·4 mg; Semaglutide 1·0 mg; Placebo

ETD semaglutide 2.4 mg: vs semaglutide 1·0 mg; vs placebo